Atty. Docket No.: PU4112US2

S/N 10/038,694

REMARKS

Claims 9-19 are pending in this application. The Examiner has withdrawn the previous rejection of claims 9-19 under 35 U.S.C. 112 first paragraph.

The Examiner has maintained the rejection of claims 9-10 under 35 USC section 103 (a) as being unpatentable over Rosenberg (US 4,894,440) in view of Warmen et al. (US 2002/0137894, Flannery et al and Chubinskaya et al (US 2002/0052358).

The Examiner states that Rosenberg teaches MS purified to homogeneity from serum-free conditioned medium obtained from cultured human embryonic kidney cells. The Examiner notes that Rosenberg does not teach the use of chondrocytes.

According to the Examiner's rejection, Warmen shows chondrocytes make CACP (MSF/SZP) and suggests that "bovine chondrocytes would make SZP." The Office Action also states Flannery teaches SZP may be purified from bovine chondrocytes and Chubinskaya teaches immortalized/non-immortalized mammalian chondrocytes. The Examiner combines the references to conclude "it would have been obvious to the person of ordinary skill in the art at the time the invention was made to use immortalized or non-immortalized chondrocytes in the method of Rosenberg et al."

Similarly claims 11-19 are rejected under 35 USC section 103 (a) as being unpatentable over Rosenberg (US 4,894,440) in view of Turner (US 2002/137894). The Examiner states Rosenberg does not expressly teach exogenous expression of MSF in cultured cells but suggests the MSF may be produced in genetically engineered organisms, or modified MSF may be produced. The Examiner states Turner teaches genetically engineered MSF for intracellular expression in bacterial host. The Examiner concludes that the references taken together teach the method of claims 11-19.

In the Applicants previous response, Applicants traversed the rejections on the basis that Rosenberg is not relevant art because the term "megakaryocyte stimulating factor" disclosed in Rosenberg is associated with thrombopoeitin and is not the same as the "megakaryocyte stimulating factor" associated with SZP. The Examiner was not persuaded that "megakaryocyte stimulating factor" in Roseberg was thrombopoeitin and indicated that the megakaryocyte stimulating factor was not listed as a designation for thrombopoeitin in the Human Gene Nomenclature database.

出一个的

Atty. Docket No.: PU4112US2

S/N 10/038.694

Applicants provide herewith search results from NCBI Entrez Gene database showing the term "megakaryocyte stimulating factor" has been used as a designation for both THPO (thrombopoietin) and PRG4 (Superficial zone protein). Since the Rosenberg reference is directed to thrombopoietin and not to superficial zone protein, it would not be obvious for one of ordinary skill in the art to use the methods of Rosenberg in combination with the other cited references to isolate SZP according to applicants' claimed method. Applicants respectfully request the rejections be withdrawn.

Claim 11 has been amended to correct typographical errors and thereby place the claims in condition for allowance.


Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

Michael M. Conger () Attorney for Applicants Registration No. 43.562

Date: January 27, 2005 GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park North Carolina 27709 Telephone: (919)483-2474

Facsimile: (919)483-7988



Restrictions on Use | Write to the Help Desk
NCBI | NLM | NIH

Jan 25 2005 16:15:24